Equasens reports stable third-quarter 2023 sales on a year-on-year basis, at €50.1 million, affected by the end of the deployment of SEGUR referenced solutions and a rather sluggish environment in the pharmaceuticals sector.

Its main Pharmagest division posted sales of 36.8 million, down slightly by 1%, but "maintaining solid growth" excluding the impact of the end of the SEGUR rollout, which made an exceptional contribution to sales in 2022.

For the first nine months of the current year, the software solutions group for healthcare professionals posted sales of 162.7 million euros, up 6% on the same period in 2022.

Copyright (c) 2023 CercleFinance.com. All rights reserved.